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Abstract
Background: Cutaneous squamous cell carcinoma (cSCC) occurs 65–200 times more in immunosuppressed organ
transplant patients than in the general population. T cells, which are targeted by the given immunosuppressive
drugs, are involved in anti-tumor immune surveillance and are functionally regulated by DNA methylation. Prior to
kidney transplantation, we aim to discover differentially methylated regions (DMRs) in T cells involved in de novo
post-transplant cSCC development.
Methods: We matched 27 kidney transplant patients with a future de novo cSCC after transplantation to 27 kidney
transplant patients without cSCC and studied genome-wide DNA methylation of T cells prior to transplantation.
From 11 out of the 27 cSCC patients, the DNA methylation of T cells after transplantation was also examined to
assess stability of the observed differences in DNA methylation. Raw methylation values obtained with the 450k
array were confirmed with pyrosequencing.
Results: We found 16 DMRs between patients with a future cSCC and those who do not develop this complication
after transplantation. The majority of the DMRs were located in regulatory genomic regions such as flanking bivalent
transcription start sites and bivalent enhancer regions, and most of the DMRs contained CpG islands. Examples of
genes annotated to the DMRs are ZNF577, coding for a zinc-finger protein, and FLOT1, coding for a protein involved in
T cell migration. The longitudinal analysis revealed that DNA methylation of 9 DMRs changed significantly after
transplantation. DNA methylation of 5 out of 16 DMRs was relatively stable, with a variation in beta-value lower
than 0.05 for at least 50% of the CpG sites within that region.
Conclusions: This is the first study demonstrating that DNA methylation of T cells from patients with a future de
novo post-transplant cSCC is different from patients without cSCC. These results were obtained before transplantation,
a clinically relevant time point for cSCC risk assessment. Several DNA methylation profiles remained relatively stable
after transplantation, concluding that these are minimally affected by the transplantation and possibly have a lasting
effect on post-transplant cSCC development.
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Background
The risk of developing cancer is markedly higher in
organ transplant patients than in the general population
[1]. The most common cancer in transplant patients is
non-melanoma skin cancer whereby cutaneous squa-
mous cell carcinoma (cSCC) occurs most frequently [2],
with an increased risk of 65–200 fold [2–4]. Not only
the incidence of cSCC increases after organ transplant-
ation, the skin cancer also behaves more aggressively.
Transplant patients experience more metastasis and
more recurrence of the cSCC: 70% of the patients de-
velop a subsequent skin cancer within 5 years [5, 6].
Identification of transplant patients at increased risk for
cSCC may allow early intervention and will improve the
quality of life for these patients.
Transplant patients are at high risk for cSCC because
of their impaired immune system due to lifelong im-
munosuppressive therapy [7–9]. Immunosuppressive
drugs used after organ transplantation suppress T cell
activity [10]. T cells are an important cell type for
anti-tumor immune surveillance (CD8+), but can also
provide a more immune-tolerant environment for the
tumor (regulatory T cells) [11, 12]. Carroll et al. [13]
showed that high numbers of peripheral regulatory CD4
+FOXP3+ cells predicted the development of a new
cSCC in kidney transplant patients who had a previous
cSCC. Also the presence of CD8+CD57hi cells, a pheno-
type associated with T cell senescence, was shown to
predict development of a subsequent cSCC in kidney
transplant patients [14]. These studies both predicted re-
currence of the cSCC; tools to predict de novo cSCC
after transplantation are currently unavailable.
Considering the recurrent nature of cSCC and the in-
creased incidence in immunocompromised transplant
patients, we hypothesized that there is a systemic defect
in patients who will develop cSCC due to an altered
state of T cell function. Such an altered state of T cell
function is a well-known consequence of loss of kidney
function [15]. T cell function is determined by the chro-
matin state of its DNA, which is a combination of epi-
genetic features such as DNA methylation, DNA
accessibility, histone modifications, and RNA expression
[16, 17]. DNA methylation is an important epigenetic
regulator of cellular function [18, 19], and high methyla-
tion in the transcription start site (TSS) of a gene is in
most cases associated with transcriptional silencing of
the corresponding gene [20].
Differential DNA methylation between transplant pa-
tients with or without a future post-transplant cSCC
might provide insight in the pathogenesis of cSCC.
However, DNA methylation is a dynamic feature and
significantly influenced by the environment [21]. After
kidney transplantation, immunosuppressive therapy is
given and the metabolic complications associated with
loss of kidney function largely disappear. Therefore, it
can be expected that changes in DNA methylation will
occur and this may also affect any DNA methylation
profiles identifying patients at risk for de novo
post-transplant cSCC. By comparing these DNA methy-
lation profiles before and after transplantation, the ex-
tent of their functional effect on post-transplant cSCC
development could be assessed.
In this retrospective study, we aimed to identify kidney
transplant patients at risk for de novo post-transplant
cSCC by studying genome-wide DNA methylation of T
cells. We analyzed samples collected before transplant-
ation and compared patients with a future de novo
post-transplant cSCC to patients without cSCC. Highly
enriched T cell populations were isolated from these pa-
tients and genome-wide DNA methylation was mea-
sured. We then searched for differentially methylated
regions (DMRs) by comparing the future cSCC patients’
methylation profiles to the non-cSCC profiles. For a sub-
set of cSCC patients, a post-transplantation sample was
available which enabled us to compare DNA methylation
before and after transplantation. A technical validation
of the raw methylation values on the array was per-
formed with pyrosequencing.
Methods
Patient samples
Anonymized biobank samples were used in this study;
this approach had been approved by the local ethical
committee (MEC-2015-642). Kidney transplant patients
with a future post-transplant cSCC were matched to kid-
ney transplant patients who have not developed an cSCC
based on gender, age (± 2 years), ethnicity, cytomegalo-
virus (CMV) status, and availability of biobank material.
We included patients with at least one cSCC after
transplantation and patients with cSCC in situ (Bowen’s
disease). Patients with a previous kidney transplantation
or another donor organ such as liver, heart, or lung were
excluded, as well as patients with a history of malignancy
prior to transplantation. Non-cSCC patients with actinic
keratosis, a pre-cancerous lesion, were excluded.
The patient cohort consisted of 27 cSCC patients and
27 non-cSCC patients who had been transplanted be-
tween 1997 and 2014. No statistical differences were
found between the clinical characteristics of the cSCC and
non-cSCC patients; however, after cell sorting, the com-
position of CD4+ and CD8+ T cells significantly differed
between the cSCC and non-cSCC patients (Table 1). One
cSCC patient had received immunosuppressive drugs
prior to an AB0-incompatible transplantation.
From 11 cSCC patients, material collected after trans-
plantation was available for a longitudinal analysis; char-
acteristics of this subset of patients are given in Table 2.
The post-transplantation samples were collected based
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on the availability of biobank material and are therefore at
different time points after transplantation (Table 3). Three
of the post-transplant samples were taken after the diag-
nosis of the first cSCC. All of these patients received
treatment, patient “p1” was treated with a topical chemo-
therapeutic agent 5-fluorouacil, patient “p2” was treated
with photodynamic therapy and surgical excision, and pa-
tient “p4” was treated with a surgical excision.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by density gradient centrifugation using standard
Ficoll-Paque procedures (GE Healthcare, Chicago, IL, US).
Isolated PBMCs were stored at − 140 °C until further use.
T cells were isolated from the PBMCs using fluorescence-
activated cell sorting (FACS) by the BD FACSAria™ ll (BD
Biosciences, San Jose, CA, US). PBMCs were stained with
anti-CD3 Brilliant Violet 510 (Biolegend, San Diego, CA,
US), anti-CD4 Pacific Blue (BD Biosciences), and
anti-CD8 APC-cy7 (BD Biosciences), and to exclude non-
viable cells, 7AAD PerCP (BD Biosciences) was used.
After cell sorting, the purities were > 92% for CD3+ cells;
samples below 90% were excluded for further analysis.
Before isolating DNA from the T cells, all patient sam-
ples were randomized to minimize batch effects. DNA
was isolated using the QIAamp DNA Micro kit (Qiagen,
Venlo, The Netherlands) according to the manufacturer’s
protocol. Purity and concentration of the isolated DNA
was assessed with the NanoDrop ND-8000 (Isogen Life
Science, Utrecht, The Netherlands). DNA degradation
was determined by gel electrophoresis; none of the sam-
ples showed significant degradation.
DNA methylation microarrays
To generate genome-wide DNA methylation data,
500 ng of genomic DNA was treated with sodium-bisul-
fite to induce methylation-dependent changes in the
DNA sequence, using the EZ DNA Methylation kit
(Zymo Research, Irvine, CA, US). DNA was then
hybridized on Infinium HumanMethylation450 arrays
(Illumina, San Diego, CA, USA) according to the manu-
facturer’s protocol, and IDAT files were generated by the
iScan BeadChip scanner (Illumina).
Table 1 Patient characteristics
cSCC Non-cSCC
N = 27 N = 27
Age (years)a 61.7 (27–77) 61.3 (27–77) p = 0.802
Gender (male) 19 (70.4%) 19 (70.4%) p = 1
Years between
Tx and first cSCCa
5.4 (0.9–12.5) – –
CMV status p = 0.46
Negative 12 (44.4%) 9 (33.3%)
Positive 15 (55.6%) 17 (63.0%)
Unknown – 1 (3.7%)
Dialysis pre-transplantation p = 0.783
Yes 16 (59.3%) 15 (55.6%)
No 11 (40.7%) 12 (44.4%)
ESRD diagnosis p = 0.058
Polycystic kidney 6 (22.2%) 1 (3.7%)
Hypertension 6 (22.2%) 3 (11.1%)
Diabetic nefropathy 1 (3.7%) 6 (22.2%)
Glomerulonefritis 3 (11.1%) 6 (22.2%)
Other 11 (40.7%) 11 (40.7%)
% CD3a 97.4 (92.4–99.5) 98.0 (95.1–99.5) p = 0.225
% CD4a 73.0 (45.1–91.4) 60.3 (34.8–80.7) p = 0.000
% CD8a 20.7 (5.8–46.2) 32.8 (14.8–60.6) p = 0.000
aMedian and range
cSCC cutaneous squamous cell carcinoma, CMV cytomegalovirus, ESDR end-stage
renal disease
Table 2 Patient characteristics longitudinal analysis
N = 11
Age at Tx (years)a 65.4 (47–75)
Gender (male) 8 (72.7%)
Years between Tx and first cSCCa 2.6 (1.1–11.5)
Years between Tx and post-Tx samplea 2.1 (0.3–13.0)
CMV acceptor
Negative 4 (36.4%)
Positive 7 (63.6%)
CMV donor
Negative 7 (63.6%)
Positive 4 (36.4%)
HLA mismatchesa 2 (0–6)
Type of immunosuppression directly after transplantation
Corticosteroids 10 (90.9%)
Tacrolimus 10 (90.9%)
MMF 10 (90.9%)
Cyclosporine 1 (9.1%)
Sirolimus 1 (9.1%)
Basiliximab induction 3 (27.3%)
ATG induction 1 (9.1%)
ESRD diagnosis
Polycystic kidney 5 (45.5%)
Hypertension 1 (9.1%)
Other 5 (45.5%)
Dialysis pre-transplantation
Yes 8 (72.7%)
No 3 (27.3%)
aMedian and range
cSCC cutaneous squamous cell carcinoma, CMV cytomegalovirus, ESDR end-
stage renal disease
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Data quality was examined using the MethylAid R pack-
age [22, 23]. All samples passed the five quality controls
performed using the default MethylAid thresholds. Probes
with a detection p value > 0.01 were removed from the
dataset as well as probes containing single nucleotide
polymorphisms. Since our patient population was a
mixture of male and female, all probes on the sex chromo-
somes were also removed. A between-array normalization
was applied to the type Ι and type ΙΙ probes separately
using the DASEN method within the wateRmelon
Bioconductor R package [23–25]. The methylation level
for each cytosine-phosphate-guanine (CpG) site was cal-
culated as the ratio of the methylated probe intensity and
the overall intensity. This is presented as a beta-value, a
value between 0 (unmethylated) and 1 (fully methylated).
After the quality controls and normalization, beta-values
of 423,289 CpG sites remained for further analysis. Both
the raw and normalized data are available via the NCBI
Gene Expression Omnibus (GEO) database with accession
number GSE103911.
Data analysis DNA methylation microarrays
To identify DNA methylation differences between the
future cSCC and non-cSCC patients, we fitted a linear
mixed effect model using the lme4 R package [26]. The
fixed effects included age, percentage CD4, percentage
CD8, and CMV status. %CD4 and %CD8 were included
in the model because we found that the composition
was different between the cSCC and non-cSCC patients
after cell sorting (Table 1). Array IDs were included as a
random effect to account for technical variation between
the arrays. Single site-specific p values were obtained
and these p values together with the genomic location of
the CpG sites were used as input into comb-p [27] to
find differentially methylated regions (DMRs).
Comb-p is a command-line tool based on a python
library to spatially correlate p values [27]. Since DNA
methylation at adjacent CpG sites is correlated, it
strengthens the data to study regions that are differen-
tially methylated instead of single sites [28, 29]. Comb-p
calculates a weighted correlation between the p values
from the single CpG site-specific analysis and combines
adjacent p values based on this correlation. A sliding
window of 500 base pair (bp) was used, and the seed
was set at p < 0.01. It then performs a false discovery rate
(FDR) adjustment to this new correlation adjusted
p values, finds regions of enrichment at an FDR cut off of
0.05, and assigns significance to those regions. Multiple
testing correction in this analysis is done using a Šidák
correction (Šidák < 0.05) [30]. The resulting DMRs were
annotated to ROADMAP reference data of primary CD3+
cells [16] to determine the CpG island content and the
chromatin state of the DMRs.
Longitudinal analysis
For 11 cSCC patients (Tables 2 and 3), we compared
DNA methylation values of the DMRs before and after
transplantation. A paired statistical analysis was done
per region. To improve clarity, only those CpG sites
within a DMR with a Δbeta-value larger than 0.05 (5%
methylation) were used for detailed graphical representa-
tion and the patients were evenly divided in four time
segments after transplantation. The CpG sites within a
region that increased or decreased less than 0.05 in
beta-value per patient were considered stable in time.
Technical validation
Performing methylation arrays for a risk assessment is
not easily applicable to clinical practice due to high costs
and labor-intensive workflow. Therefore, we tested
whether we could obtain the same methylation values
with bisulfite pyrosequencing, an easy technique to
quantitatively measure single-site DNA methylation [31].
CpG sites within the DMRs 2 and 3 were analyzed in
the same DNA samples that were used for the array ana-
lysis. Of 10 patients, a mixture of cSCC and non-cSCC
patients, 200 ng genomic DNA was bisulfite converted
using the EZ DNA Methylation-Direct kit (Zymo
Research) according to the manufacturer’s protocol. The
bisulfite-treated DNA was then amplified by polymerase
chain reaction (PCR) using the Pyromark PCR kit
(Qiagen). Primers for PCR and pyrosequencing were
designed using PyroMark Assay Design 2.0 software
(Qiagen). The PCR primers, melting temperatures, and
amplicon sizes for the different PCR products can be
found in Additional file 1 together with the specific PCR
programs for each DMR.
Table 3 Time points longitudinal analysis
Patient Time after
Tx (y)
Time between
Tx and first cSCC (y)
Comment
p1 13.0 11.0 Material obtained after
diagnosis of first cSCC
p2 7.7 4.1 Material obtained after
diagnosis of first cSCC
p3 6.9 7.7
p4 3.4 2.4 Material obtained after
diagnosis of first cSCC
p5 0.9 4.7
p6 2.1 2.6
p7 0.3 1.6
p8 1.1 2.0
p9 1.1 1.1
p10 0.6 2.2
p11 5.0 11.5
Tx transplantation, cSCC cutaneous squamous cell carcinoma, y years
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After confirming the amplicon size by gel electrophor-
esis, the PCR products were sequenced using a Pyro-
Mark Q24 pyrosequencer (Qiagen). Minor adjustments
were made to the manufacturer’s protocol: to immobilize
the PCR product 1 μL Streptadivin Sepharose High Per-
formance Beads (GE Healthcare) was used per sequence
reaction and annealing of the sequence primers was
done for 3 min at 80 °C. The sequence primers were
added at a concentration of 10 μM. Human high and
low methylated DNA (EpigenDx, Hopkinton, MA, USA)
were used as controls. DNA methylation percentages
were calculated by PyroMark Q24 software (Qiagen).
Statistical analysis
Differences in characteristics between the future cSCC
and non-cSCC patients were statistically tested using
SPSS version 21.0 (IBM Corp., Armonk, NY, US). The
Mann-Whitney U test was used for the continuous vari-
ables and χ2 test for the categorical variables. Data pro-
cessing and statistical analysis of all the microarray data
was done in RStudio version 1.0.136 (Rstudio Inc., Bos-
ton, MA, US) with R version 3.2.5 [24]. Cohen’s D was
calculated on the residuals of the linear mixed effect
model by the formula D = (meancSCC −meannon-cSCC)/
sdpooled in R. Analysis of the differences between methy-
lation in pre-transplantation and post-transplantation
samples was done using a paired Wilcoxon ranked sum
test using R. Correlation between the DNA methylation
levels quantified by pyrosequencing and the beta-values
of the Illumina 450k arrays was calculated using Spear-
man’s rank correlation coefficient using SPSS. All
statistical tests were two-tailed, and a p < 0.05 was con-
sidered statistically significant.
Results
Differentially methylated regions
To identify DMRs in T cells between patients who will
develop cSCC after kidney transplantation and those
without cSSC, we analyzed genome-wide DNA methyla-
tion of kidney transplant patients before transplantation.
After cell sorting the T cells, we observed a difference in
CD4/CD8 composition between the future cSCC and
non-cSCC patients’ T cells. The future cSCC patients
had a higher percentage of CD4+ cells than the
non-cSCC patients (p < 0.001; Table 1). For this reason,
we included the percentage CD4+ and CD8+ in the lin-
ear mixed model as covariates, thereby avoiding poten-
tially biased results with respect to the differences in
DNA methylation. None of the single-site p values
passed the multiple testing correction (Additional file 2:
Figure S1); therefore, we continued to DMR analysis.
We found 16 regions significantly differentially meth-
ylated between the future cSCC and non-cSCC pa-
tients. In Table 4, the genes annotated to the DMRs,
the genomic location of the DMRs according to the
hg19 genome build (UCSC Genome Browser), and the
number of array probes within the regions are pre-
sented, and the gene functions are shortly described.
Also the Cohen’s D is presented per region which is a
measure for effect size taking into account the standard
deviation in the two groups. Out of the 16 DMRs, 5
Table 4 Resulting differentially methylated regions of the pre-transplantation analysis
Genomic location (hg19) Length DMR (bp) No. of probes Regional p value Cohen’s D DMR state
1 chr19:4531638-4531962 324 4 3.57·10−11 0.95 Hyper
2 chr5:63461216-63461931 715 10 5.51·10−10 − 0.54 Hypo
3 chr3:44753865-44754399 534 11 8.18·10−10 − 0.60 Hypo
4 chr2:3699195-3699564 369 5 9.35·10−10 0.81 Hyper
5 chr6:168197177-168197700 523 6 6.54·10−9 − 0.68 Hypo
6 chr4:165898666-165898968 302 8 1.49·10−8 0.54 Hyper
7 chr5:140305947-140306459 512 10 2.38·10−8 − 0.53 Hypo
8 chr2:177014555-177015126 571 12 4.35·10−8 0.41 Hyper
9 chr1:185703201-185703689 488 12 1.89·10−7 − 0.42 Hypo
10 chr6:30698584-30698988 404 11 2.90·10−7 − 0.48 Hypo
11 chr19:52391078-52391606 528 12 6.59·10−7 0.58 Hyper
12 chr8:54164051-54164443 392 8 1.20·10−6 − 0.48 Hypo
13 chr7:51539131-51539584 453 5 1.61·10−6 − 0.64 Hypo
14 chr6:88757302-88757704 402 6 1.80·10−6 − 0.55 Hypo
15 chr2:74875227-74875549 322 8 1.45·10−6 − 0.47 Hypo
16 chr8:96085385-96085690 305 3 1.22·10−5 − 0.74 Hypo
DMR differentially methylated region, chr chromosome, bp base pair
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were hyper methylated and 11 were hypo methylated in
the future cSCC patients.
Genomic characteristics of the DMRs
Since CpG islands are often found near transcription start
sites (TSS) and are involved in transcription initiation
[32], methylation of CpG islands could have a downstream
effect on gene activity. Together with the cell-type-specific
chromatin state of the DNA, this could indicate the bio-
logical function of a genomic region. In Fig. 1a, the CpG
island content is depicted for all regions together and the
individual DMRs separately; the array content is given as
reference. The 16 DMRs are enriched for CpG islands,
slightly less CpG sites are within the shores (< 2 kb flank-
ing CpG islands), and CpG sites within shelves (< 2 kb
flanking shores) are absent in these DMRs. For the
chromatin state, we annotated the CpG probes within
each DMR to ROADMAP epigenomics reference data of
primary T cells using the 15-state model [16] (Fig. 1b).
Although this might not be an accurate representation of
the chromatin state within the T cells we analyzed, it does
provide a general perspective on functional and primary T
cell-specific characteristics of the genomic region where
the DMRs are located. The chromatin states “flanking bi-
valent TSS/enh” and “bivalent enhancer” are enriched in
our results; also 7 out of the 16 DMRs are within re-
pressed or weakly repressed polycomb which is a slight
enrichment compared to the array content.
DNA methylation of the DMRs after transplantation
To study whether DNA methylation of the 16 DMRs
changed after transplantation, we compared beta-values
a
b
Fig. 1 The genomic characteristics of the CpG sites within each DMR. a CpG island content for all regions together and the individual DMRs
separately, the array content is given as reference. The color represents the CpG island content of each CpG site within that region according to
the legend below the graph. b Primary T cell-specific chromatin state according to the 15-state model of the ROADMAP epigenomics reference
data [16] for all regions together and the individual DMRs separately, the array content is given as reference. The color represents the primary T
cell-specific chromatin state of the CpG sites within that region according to the legend below the graph
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of 11 cSCC patients before and after transplantation.
Figure 2a shows the mean difference in beta-value which
is an average of all CpG sites per region for all 11 pa-
tients together. Overall mean beta-value increased after
transplantation. In most regions, there were CpG sites
that increased and CpG sites that decreased, therefore
showing a mean difference close to zero. All differences
in beta-value per DMR and per patient can be found in
Additional file 2: Figure S2. A paired Wilcoxon ranked
sum test per region resulted in 9 regions that were sig-
nificantly different after transplantation, after a Bonfer-
roni multiple testing correction (Table 5).
All CpG sites showed variation within all patients;
therefore, to reduce noise and improve clarity, we con-
sidered a CpG site that increased or decreased less than
0.05 in beta-value stable. None of the DMRs were 100%
stable in time (Fig. 2b); however, some regions showed
more stability than others. DMRs 1, 5, 9, 14, and 16
showed at least 50% stable CpG sites whereas in DMRs
4, 11, and 13, none of the sites were stable in time. A
more detailed graphical representation of the changes in
beta-value per region, per patient, and in time can be
found in Additional file 2: Figure S3.
We also analyzed the mean methylation differences per
patient to examine a possible relationship with time after
transplantation and with time to clinical onset of the
cSCC (Table 3). These mean differences were relatively
small in 5 out of 11 patients (Δbeta-value < 0.01) (Fig. 3).
Mean methylation differences were not significantly corre-
lated to the time between transplantation and clinical
onset of cSCC (p = 0.46), nor to time after transplantation
(p = 0.50), nor to time between post-transplant sample
and the clinical onset of cSCC (p = 0.09).
Technical validation
To confirm the raw beta-values obtained with the 450k
array, we performed pyrosequencing analysis of two
DMRs (six CpG sites) on the same DNA samples that
were analyzed on the array. The DNA methylation
values obtained with pyrosequencing were slightly lower
a
b
Fig. 2 Stability of the 16 DMRs. a Mean difference in beta-value per region between pre-transplant and post-transplant samples. The difference is
calculated per CpG site for each individual patient and is then averaged over all CpG sites per region for all 11 cSCC patients together. b Percentage of
CpG sites that show a Δbeta-value of less than 0.05 presented per region. The numbers within each bar represent the number of stable CpG sites
from the total sites within that region
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than the beta-values obtained with the arrays; this was a
consistent deviation across all samples (Fig. 4). There
was a strong correlation between the results obtained
with the two different techniques; the two sites within
DMR 2 had a Spearman correlation coefficient (r) of
0.95 (p < 0.0001) and the four sites within DMR 3 had
an r of 0.88 (p < 0.0001).
Discussion
Our results demonstrate that the T cells of patients with
a future post-transplant cSCC have different DNA
methylation profiles compared to the T cells of kidney
transplant patients without cSCC. To our knowledge,
this is the first study to show DNA methylation
differences in peripheral T cells between patients who
develop a post-transplant cSCC and those who do not
develop cSCC. In addition, we were able to obtain these
results at a clinically relevant time point, before trans-
plantation. The retrospective nature of this study
allowed us to carefully match the future cSCC patients
to non-cSCC patients and examine the DNA methyla-
tion within a highly enriched T cell population.
The observed differences in DNA methylation are pre-
dominantly located in CpG islands and bivalent enhancer
regions (Fig. 1). Since these are both regulatory genomic
regions, it is likely that these differences have a down-
stream effect in T cells and that differential DNA methyla-
tion within these regions could affect T cell function.
However, the effect of differential methylation at enhancer
regions is difficult to assess since enhancers can regulate
genes at large distances in the genome [33]. RNA sequen-
cing would reveal any distal gene regulation by these en-
hancers; however, that was outside the scope of this study.
Here, we focus on the genes that were annotated solely on
the basis of close proximity to the DMR.
Out of the 16 DMRs, a few could be associated to can-
cer by studying literature. Even though these studies
were not performed in T cells but mostly in the tumor
tissue itself, we can speculate on a possible relationship
with post-transplant cSCC development. An example is
DMR 11 (annotated to ZNF577) which was hypermethy-
lated in our future cSCC patients and showed to be
hypermethylated in SCC and adenocarcinoma of the
lungs [34]. In addition, an inverse correlation between
ZNF577 gene expression and its DNA methylation was
found [35]. DMR 10, which was situated within the ac-
tively transcribed gene FLOT1, was hypo methylated in
our cSCC patients. At first sight, it is an interesting gene
due to its involvement in migration of hematopoietic
cells [36] and it showed to promote invasion and metas-
tasis of several SCC subtypes when overexpressed [37,
Fig. 3 Mean difference in beta-value per patient between pre-transplant and post-transplant sample. The difference was calculated per CpG site
for each individual patient and was then averaged over all CpG sites per patient
Table 5 Results of statistical tests between pre-transplant and
post-transplant beta-values per region
DMR p value Bonferroni correction
1 0.87
2 1.83·10−6 2.92·10−5
3 2.03·10−5 3.25·10−4
4 0.002 0.038
5 0.082
6 0.55
7 8.09·10−8 1.29·10−6
8 0.002 0.033
9 1.51·10−5 2.41·10− 4
10 3.71·10−13 5.93·10−12
11 0.028
12 9.42·10−5 0.002
13 0.14
14 0.32
15 5.48·10−5 8.78·10−4
16 0.33
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38]. However, in the longitudinal analysis, this was the
most varying region (Table 5) with the majority of CpG
sites increasing in DNA methylation after transplant-
ation (Additional file 2: Figure S2J). This suggests that
this region is greatly influenced by transplantation and it
remains unsure how this differential methylation at time
of transplantation could affect post-transplant cSCC
development.
A kidney transplantation is a procedure with major
health effects for an end-stage renal disease (ESRD) pa-
tient, and these effects influence DNA methylation. Sev-
eral studies have shown that blood DNA methylation is
associated to kidney function [39, 40]. In addition to
that, we showed in a previous study that DNA methyla-
tion of T cells can also be modulated by the immuno-
suppressive medication that kidney transplant patients
receive after transplantation [41]. We therefore expected
variation between the pre-transplant and post-transplant
DNA methylation values in the longitudinal analysis. In-
deed, we see that beta-values were significantly different
in 9 of the 16 DMRs (Table 4). More interestingly, all
but one region increased in mean DNA methylation
after transplantation (Fig. 2). This could be a general ef-
fect of the transplantation and is in line with findings by
Boer et al. [42] showing increased DNA methylation at
the PD1 and IFNγ gene 3 months after transplantation.
To determine which regions could have a lasting effect
on post-transplant cSCC development, we examined sta-
bility of the 16 DMRs after transplantation and consid-
ered the CpG sites that stayed within a Δbeta-value of
0.05 stable. DMRs 1, 5, 14, and 16 have 50% or more
stable CpG sites and were also not significantly different
in a paired statistical analysis (Table 4), suggesting that
these differential methylation profiles might have a pro-
longed effect after transplantation. Considering the
possibility of distal gene regulation by these DMRs, their
functional effect could be determined by a genome-wide
RNA and protein analysis within these T cells. Addition-
ally, to overcome the variability in sampling time points
within this study, a prospective study with sampling at
regular intervals after transplantation would further as-
sess stability of these DMRs and their function in
post-transplant cSCC development.
The development of post-transplant cSCC is the result
of a series of events involving different risk factors [2].
Known examples are age, skin type, gender, and possibly
immune phenotype [43]. After cell sorting the T cells,
we found significantly higher percentages of CD4+ T
cells and consequently lower percentages of CD8+ T
cells in the future cSCC patients (Table 1). This suggests
that an altered CD4/CD8 ratio might be another risk
factor for post-transplant cSCC. There is no consensus
in literature on the CD4/CD8 ratio in relation to
post-transplant cancer development. In contrast to our
findings Thibaudin et al. [44] found, over a 10-year ob-
servation period, consistently lower counts of CD4+ T
cells in patients with future post-transplant malignancy.
Although this was not evident at time of transplantation
but occurred thereafter. Whereas Bottomley et al. [14]
found no significant difference in CD4+ T cell and CD8
+ T cell counts or percentages between cSCC and
non-cSCC kidney transplant patients.
The relative small sample size in this study is a conse-
quence of selective matching and availability of biobank
material. This combined with the single-center design of
the study leads to cautious interpretation of the findings.
Moreover, we acknowledge that patient pairs can never
be perfectly matched. Since we are studying T cells and
not skin tissue, where the differences between healthy
and malignant tissue are much larger, it was expected
a b
Fig. 4 Methylation values on the array and by pyrosequencing of six CpG sites within two DMRs. a DMR 2 (r = 0.95; p < 0.0001). b DMR 3 (r = 0.88;
p < 0.0001). The CpG sites correspond to the CpG sites within the DMRs (Table 4)
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that the differences would be subtle. Despite these limi-
tations, the results of this study are a promising first step
towards early risk assessment for post-transplant cSCC.
To assess the clinical value of these findings, a validation
in a different and larger cohort of transplant patients is
necessary in addition to our technical validation [45, 46].
Conclusion
The findings presented here demonstrate the potential
of studying DNA methylation of the T cells to identify
kidney transplant patients at risk for de novo
post-transplant cSCC [47]. We showed that there were
systemic differences between future cSCC and non-
cSCC patients prior to transplantation. A longitudinal
analysis showed that several DNA methylation profiles
remained relatively stable after transplantation, suggest-
ing a lasting effect on the development of de novo cSCC
after transplantation. In the future, identification of pa-
tients at increased risk for post-transplant cSCC before
transplantation will allow for early clinical interventions
such as regular visits to the dermatologist and stricter
lifestyle advice to the patient to minimize additional sun
exposure [48]. Ultimately, it may lead to adjustment of
the immunosuppressive load but this remains a fine bal-
ance between reducing the risk for cancer and causing
irreversible damage to the allograft.
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